Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MSH2 loss |
Therapy | Cytarabine |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MSH2 loss | colorectal cancer | sensitive | Cytarabine | Preclinical | Actionable | In a preclinical study, colorectal cancer cells deficient in MSH2 had increased sensitivity to Cytosar-U (cytarabine) in culture (PMID: 23361057). | 23361057 |
PubMed Id | Reference Title | Details |
---|---|---|
(23361057) | Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. | Full reference... |